Advertisement
Advertisement

IBRX

IBRX logo

ImmunityBio, Inc. Common Stock

7.91
USD
Sponsored
-0.21
-2.64%
May 13, 10:31 UTC -4
Open

IBRX Earnings Reports

Positive Surprise Ratio

IBRX beat 23 of 42 last estimates.

55%

Next Report

Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$50.07M
/
-$0.07
Implied change from Q1 26 (Revenue/ EPS)
+13.26%
/
-12.50%
Implied change from Q2 25 (Revenue/ EPS)
+89.47%
/
-30.00%

ImmunityBio, Inc. Common Stock earnings per share and revenue

On May 07, 2026, IBRX reported earnings of -0.08 USD per share (EPS) for Q1 26, missing the estimate of -0.07 USD, resulting in a -12.04% surprise. Revenue reached 44.21 million, compared to an expected 43.93 million, with a 0.63% difference. The market reacted with a -7.40% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 4 analysts forecast an EPS of -0.07 USD, with revenue projected to reach 50.07 million USD, implying an decrease of -12.50% EPS, and increase of 13.26% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Vor Biopharma Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.78
Actual
-$0.73
Surprise
+7.38%
logo
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
logo
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
logo
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
logo
Protalix BioTherapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.01
Actual
$0.22
Surprise
+2278.22%
logo
Immunic, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.93
Actual
-$1.08
Surprise
-16.03%
logo
Humacyte, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.11
Actual
-$0.09
Surprise
+24.05%
logo
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
logo
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-
Actual
-$0.05
Surprise
-
logo
PDS Biotechnology Corporation Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.13
Surprise
+15.03%
FAQ
For Q1 2026, ImmunityBio, Inc. Common Stock reported EPS of -$0.08, missing estimates by -12.04%, and revenue of $44.21M, 0.63% above expectations.
The stock price moved down -7.4%, changed from $8.38 before the earnings release to $7.76 the day after.
The next earning report is scheduled for Aug 03, 2026.
Based on 4 analysts, ImmunityBio, Inc. Common Stock is expected to report EPS of -$0.07 and revenue of $50.07M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement